407 related articles for article (PubMed ID: 22884806)
1. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.
Rubin LJ
Life Sci; 2012 Oct; 91(13-14):517-21. PubMed ID: 22884806
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy evaluation of ambrisentan in pulmonary hypertension.
Vizza CD; Fedele F; Pezzuto B; Rubin LJ
Expert Opin Drug Saf; 2012 Nov; 11(6):1003-11. PubMed ID: 22861496
[TBL] [Abstract][Full Text] [Related]
3. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
[TBL] [Abstract][Full Text] [Related]
4. Ambrisentan, an endothelin receptor type A-selective endothelin receptor antagonist, for the treatment of pulmonary arterial hypertension.
Kingman M; Ruggiero R; Torres F
Expert Opin Pharmacother; 2009 Aug; 10(11):1847-58. PubMed ID: 19601701
[TBL] [Abstract][Full Text] [Related]
5. An update on the use of ambrisentan in pulmonary arterial hypertension.
D'Alto M
Ther Adv Respir Dis; 2012 Dec; 6(6):331-43. PubMed ID: 22933513
[TBL] [Abstract][Full Text] [Related]
6. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Dranitsaris G; Mehta S
Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
[TBL] [Abstract][Full Text] [Related]
7. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
Aversa M; Porter S; Granton J
Drug Saf; 2015 May; 38(5):419-35. PubMed ID: 25792028
[TBL] [Abstract][Full Text] [Related]
8. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
Steiner MK; Preston IR
Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
[TBL] [Abstract][Full Text] [Related]
9. Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells.
Gatfield J; Mueller Grandjean C; Sasse T; Clozel M; Nayler O
PLoS One; 2012; 7(10):e47662. PubMed ID: 23077657
[TBL] [Abstract][Full Text] [Related]
10. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Kabunga P; Coghlan G
Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of ambrisentan.
Buckley MS; Wicks LM; Staib RL; Kirejczyk AK; Varker AS; Gibson JJ; Feldman JP
Expert Opin Drug Metab Toxicol; 2011 Mar; 7(3):371-80. PubMed ID: 21299444
[TBL] [Abstract][Full Text] [Related]
12. Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension.
O'Callaghan DS; Savale L; Yaïci A; Natali D; Jaïs X; Parent F; Montani D; Humbert M; Simonneau G; Sitbon O
Expert Opin Pharmacother; 2011 Jul; 12(10):1585-96. PubMed ID: 21504371
[TBL] [Abstract][Full Text] [Related]
13. The Clinical Efficacy of Endothelin Receptor Antagonists in Patients with Pulmonary Arterial Hypertension.
Maki H; Hara T; Tsuji M; Saito A; Minatsuki S; Inaba T; Amiya E; Hosoya Y; Hatano M; Morita H; Yao A; Kinugawa K; Komuro I
Int Heart J; 2020; 61(4):799-805. PubMed ID: 32728000
[TBL] [Abstract][Full Text] [Related]
14. Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
Price LC; Howard LS
Am J Cardiovasc Drugs; 2008; 8(3):171-85. PubMed ID: 18533738
[TBL] [Abstract][Full Text] [Related]
15. A review of pulmonary arterial hypertension: role of ambrisentan.
Barst RJ
Vasc Health Risk Manag; 2007; 3(1):11-22. PubMed ID: 17583171
[TBL] [Abstract][Full Text] [Related]
16. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
Mucke HA
IDrugs; 2009 Jun; 12(6):366-75. PubMed ID: 19517317
[TBL] [Abstract][Full Text] [Related]
17. Role of ambrisentan in the management of pulmonary hypertension.
Hrometz SL; Shields KM
Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
[TBL] [Abstract][Full Text] [Related]
18. Functional estimation of endothelin-1 receptor antagonism by bosentan, macitentan and ambrisentan in human pulmonary and radial arteries in vitro.
Angus JA; Soeding PF; Hughes RJA; Wright CE
Eur J Pharmacol; 2017 Jun; 804():111-116. PubMed ID: 28300593
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.
Venitz J; Zack J; Gillies H; Allard M; Regnault J; Dufton C
J Clin Pharmacol; 2012 Dec; 52(12):1784-805. PubMed ID: 22205719
[TBL] [Abstract][Full Text] [Related]
20. Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.
Humbert M; Simonneau G
Nat Clin Pract Rheumatol; 2005 Dec; 1(2):93-101. PubMed ID: 16932638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
